Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + benzydamine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oromucosal, Topical, Vaginal
01
Overview
This appears to be a combination used in clinical studies where benzydamine is being compared to placebo. Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) with local anesthetic and analgesic properties. It has distinct pharmacological properties from other NSAIDs, as its anti-inflammatory mechanism is not strictly explained by interference with prostaglandin synthesis. Benzydamine is primarily used for local inflammatory conditions of the oral and vaginal mucosa.
- Brand names
- Tantum Verde
02
Targets
PLA2 (Phospholipase A2 group IID)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)IL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on placebo + benzydamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + benzydamine.